Efficacy of trans-Tenon’s retrobulbar triamcinolone infusion in uveitis (numbers are number of eyes (%))
| Efficacy assessed by: funduscopy* | FA* | OCT* | Visual acuity improvement† | |
|---|---|---|---|---|
| *Denominator represents number of eyes in which the examination was performed both before and within 3 months after initial triamcinolone infusion, and numerator represents eyes that showed improvement. Improvement by funduscopy for vitritis was defined as decrease in the vitreous haze score (published scale 1–5).20 For cystoid macular oedema (CMO), funduscopic improvement was defined as resolution of intraretinal cysts. For retinal vasculitis, funduscopic improvement was defined as at least 50% decreased heamorrhages and exudates along inflamed vessels. Improvement by FA for CMO was defined as decreased pooling in late images of the fovea (arbitrary scale 1–4), and for retinal vasculitis as decreased vascular leakage or staining (arbitrary scale 1–4) in late images. Improvement by OCT for CMO was defined as at least 50% decreased height of retinal thickness in the center of the fovea and return of the normal foveal configuration. | ||||
| †Denominator represents eyes with a best corrected visual acuity of 0.155 logMAR or worse at the time of initial triamcinolone infusion, and numerator represents eyes in this group that had a 0.200 logMAR or greater visual acuity improvement within 3 months. | ||||
| FA = fluorescein angiography; OCT = optical coherence tomography; NA = not applicable. | ||||
| Vitritis (n = 26) | 25/26 (96) | NA | NA | 11/14 (79) |
| Cystoid macular oedema (n = 22) | 18/22 (82) | 4/5 (80) | 12/15 (80) | 11/16 (69) |
| Posterior retinal vasculitis (n = 3) | 1/3 (33) | 1/1 (100) | NA | 0/1 (0) |
| Total | 44/51 (86) | 22/31 (71) | ||